CVS stock analyst sentiment

What happened: CVS Health (NYSE: CVS) stock gained momentum on Tuesday, driven by price target increases from two analysts who maintained 'buy' recommendations. Jim Cramer, on multiple occasions, praised CVS's upcoming quarter and the company's cheap valuation. Merck & Co. (MRK), a pharmaceutical competitor, maintained a neutral outlook from analysts.

Market impact: The bullish sentiment around CVS pushed the stock up, benefiting investors and potentially attracting more buyers. The pharmacy sector saw increased interest, with CVS's strong performance driving some of this momentum. Merck, however, remained relatively unaffected by these developments.

What to watch next: CVS's earnings report on May 3 will confirm or refute Cramer's bullish predictions. Additionally, any further analyst upgrades or downgrades could significantly impact CVS's stock price. For Merck, the upcoming FDA decision on its Keytruda label expansion on May 12 will be a critical catalyst.